Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans

Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Drug Metabolism and Disposition (Impact Factor: 3.33). 01/2006; 34(1):69-74. DOI: 10.1124/dmd.105.006312
Source: PubMed

ABSTRACT Phytochemical-mediated modulation of P-glycoprotein (P-gp) and other drug transporters may underlie many herb-drug interactions. Serial serum concentration-time profiles of the P-gp substrate, digoxin, were used to determine whether supplementation with milk thistle or black cohosh modified P-gp activity in vivo. Sixteen healthy volunteers were randomly assigned to receive a standardized milk thistle (900 mg daily) or black cohosh (40 mg daily) supplement for 14 days, followed by a 30-day washout period. Subjects were also randomized to receive rifampin (600 mg daily, 7 days) and clarithromycin (1000 mg daily, 7 days) as positive controls for P-gp induction and inhibition, respectively. Digoxin (Lanoxicaps, 0.4 mg) was administered orally before and at the end of each supplementation and control period. Serial digoxin serum concentrations were obtained over 24 h and analyzed by chemiluminescent immunoassay. Comparisons of area under the serum concentration time curves from 0 to 3 h (AUC(0-3)), AUC(0-24), Cmax, apparent oral clearance of digoxin (CL/F), and elimination half-life were used to assess the effects of milk thistle, black cohosh, rifampin, and clarithromycin on digoxin pharmacokinetics. Rifampin produced significant reductions (p < 0.01) in AUC(0-3), AUC(0-24), and Cmax, whereas clarithromycin increased these parameters significantly (p < 0.01). Significant changes in digoxin half-life and CL/F were also observed with clarithromycin. No statistically significant effects on digoxin pharmacokinetics were observed following supplementation with either milk thistle or black cohosh, although digoxin AUC(0-3) and AUC(0-24) approached significance (p = 0.06) following milk thistle administration. When compared with rifampin and clarithromycin, supplementation with these specific formulations of milk thistle or black cohosh did not appear to affect digoxin pharmacokinetics, suggesting that these supplements are not potent modulators of P-gp in vivo.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The cardinal climacteric symptoms of hot flushes and night sweats affect 24-93% of all women during the physiological transition from reproductive to post-reproductive life. Though efficacious, hormonal therapy and partial oestrogenic compounds are linked to a significant increase in breast cancer. Non-hormonal treatments are thus greatly appreciated. This systematic review of published hormonal and non-hormonal treatments for climacteric, and breast and prostate cancer-associated hot flushes, examines clinical efficacy and therapy-related cancer risk modulation. A PubMed search included literature up to June 19, 2014 without limits for initial dates or language, with the search terms, (hot flush* OR hot flash*) AND (clinical trial* OR clinical stud*) AND (randomi* OR observational) NOT review). Retrieved references identified further papers. The focus was on hot flushes; other symptoms (night sweats, irritability, etc.) were not specifically screened. Included were some 610 clinical studies where a measured effect of the intervention, intensity and severity were documented, and where patients received treatment of pharmaceutical quality. Only 147 of these references described studies with alternative non-hormonal treatments in post-menopausal women and in breast and prostate cancer survivors; these results are presented in Additional file 1. The most effective hot flush treatment is oestrogenic hormones, or a combination of oestrogen and progestins, though benefits are partially outweighed by a significantly increased risk for breast cancer development. This review illustrates that certain non-hormonal treatments, including selective serotonin reuptake inhibitors, gabapentin/pregabalin, and Cimicifuga racemosa extracts, show a positive risk-benefit ratio. Key pointsSeveral non-hormonal alternatives to hormonal therapy have been established and registered for the treatment of vasomotor climacteric symptoms in peri- and post-menopausal women.There are indications that non-hormonal treatments are useful alternatives in patients with a history of breast and prostate cancer. However, confirmation by larger clinical trials is required.
    SpringerPlus 12/2015; 4(1). DOI:10.1186/s40064-015-0808-y
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is common to utilise herbal extracts such as Silybum marianum and Rosmarinus officinalis in naturopathic practice to support hepatic function and improve oestrogen clearance, but what pharmacodynamic evidence is there to support this hypothesis? This article explores the potential use of these two traditional hepatic herbs for the potential treatment of uterine fibroids via and their action on specific CYP450 enzymes. Uterine fibroids are benign smooth muscle overgrowths which occur in various locations in the myometrium and develop from an unknown cause. There is however a wide diversity of known promoters involved in the pathogenesis including steroid hormones, such as oestrogen. Excessive oestrogen synthesis from aromatase P450 can lead to an overexpression of alpha (ER-í µí»¼) and beta (ER-í µí»½) oestrogen receptors, which through binding activity, causes a cascade of growth factors contributing to fibroid development. Considering this increased oestrogen activity has been implicated in stimulating uterine tissue, a novel approach to treating uterine fibroids is by inducing CYP1A1 and inhibiting CYP3A4 to improve the ratio between 2:16 hydroxy catechol oestrogens. Silybum marianum has shown potential in inhibiting CYP3A4 activity in vitro, but evidence from two small clinical trials did not support this. Rosmarinus officinalis shows promise by improving 2:16 hydroxy catechol oestrogen ratio equilibrium in vivo by inducing CYP1A1 and inhibiting CYP3A4 activity. Rosmarinus officinalis may have a role in altering these pathways and therefore may help to reduce the excessive uterotropic action of oestrogen and its metabolites by shifting the metabolism of oestrogen to a less proliferative pathway, but further clinical research is required.
  • [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT An evidence-based systematic review of black cohosh (Cimicifuga racemosa, Actaea racemosa) by the Natural Standard Research Collaboration consolidates the safety and efficacy data available in the scientific literature using a validated, reproducible grading rationale. This article includes written and statistical analysis of clinical trials, plus a compilation of expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.
    Journal of Dietary Supplements 08/2014; DOI:10.3109/19390211.2014.946731

Full-text (2 Sources)

Available from
Jun 10, 2014